ATE527998T1 - Illudin-analoga als krebsmittel - Google Patents

Illudin-analoga als krebsmittel

Info

Publication number
ATE527998T1
ATE527998T1 AT06800754T AT06800754T ATE527998T1 AT E527998 T1 ATE527998 T1 AT E527998T1 AT 06800754 T AT06800754 T AT 06800754T AT 06800754 T AT06800754 T AT 06800754T AT E527998 T1 ATE527998 T1 AT E527998T1
Authority
AT
Austria
Prior art keywords
analogas
illudin
cancer medicine
tumors
vivo
Prior art date
Application number
AT06800754T
Other languages
English (en)
Inventor
Trevor C Mcmorris
Michael J Kelner
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE527998T1 publication Critical patent/ATE527998T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
    • C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06800754T 2005-08-03 2006-08-03 Illudin-analoga als krebsmittel ATE527998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70501705P 2005-08-03 2005-08-03
PCT/US2006/030439 WO2007019308A2 (en) 2005-08-03 2006-08-03 Illudin analogs useful as anticancer agents

Publications (1)

Publication Number Publication Date
ATE527998T1 true ATE527998T1 (de) 2011-10-15

Family

ID=37727922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06800754T ATE527998T1 (de) 2005-08-03 2006-08-03 Illudin-analoga als krebsmittel

Country Status (5)

Country Link
US (1) US7655695B2 (de)
EP (1) EP1909783B1 (de)
JP (1) JP4989648B2 (de)
AT (1) ATE527998T1 (de)
WO (1) WO2007019308A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
WO2015157578A2 (en) 2014-04-10 2015-10-15 Af Chemicals, Llc Affinity medicant conjugates
US10285955B2 (en) 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
US11135182B2 (en) 2014-04-10 2021-10-05 Af Chemicals, Llc Affinity medicant conjugates
AU2019335222B2 (en) * 2018-09-04 2025-07-03 Lantern Pharma Inc. Illudin analogs, uses thereof, and methods for synthesizing the same
AU2019361781A1 (en) * 2018-10-14 2021-06-03 Lantern Pharma Inc. Methods for the treatment of solid tumor cancers using illudins and biomarkers
US11160807B1 (en) 2018-12-11 2021-11-02 Af Chemicals, Llc Methods, compositions and devices for treating cancer with illudofulvenes
US11591295B2 (en) 2019-11-25 2023-02-28 Af Chemicals Llc Affinity illudofulvene conjugates
CN115605191A (zh) * 2020-04-10 2023-01-13 蓝腾制药公司（Us） 用于治疗脑癌或cns癌症的羟基脲甲基-酰基富烯
WO2021226592A1 (en) * 2020-05-08 2021-11-11 Lantern Pharma Inc. Method for treating pancreatic cancer
AU2021411947A1 (en) 2020-12-29 2023-08-17 Lantern Pharma Inc. Method for treating rhabdoid tumors
AU2022205447A1 (en) * 2021-01-08 2023-07-27 Lantern Pharma Inc. Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene
JP2024513966A (ja) * 2021-04-12 2024-03-27 ランタン ファルマ インコーポレイテッド 肺がん及び非小細胞肺がんを処置する方法
KR20240004543A (ko) * 2021-05-03 2024-01-11 랜턴 파마 인코포레이티드 혈액암을 치료하는 방법
MX2024001314A (es) * 2021-07-29 2024-04-30 Lantern Pharma Inc Tratamiento de cánceres con combinaciones del inhibidor de parp y acilfulvenos.
WO2024249636A2 (en) * 2023-05-30 2024-12-05 Lantern Pharm Inc. Treating cancers with combinations of anti-cd20 antibody and acylfulvenes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459157A (en) * 1891-09-08 Running-gear for vehicles
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4612302A (en) * 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
JPS62234040A (ja) 1986-04-02 1987-10-14 Kyowa Hakko Kogyo Co Ltd Ｄｃ１０４３物質
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE68913995T2 (de) 1989-09-27 1994-08-25 Mo Ni Skij I Glaznych Boleznej Zusammensetzung zur behandlung progressiver myopie.
DK0565519T3 (da) 1989-10-03 1996-09-23 Univ California Illudinanaloge som antitumormidler
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
HU208115B (en) * 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
EP0450761A1 (de) * 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclische Oxtocin-Antagonisten
KR900016822A (ko) * 1990-04-20 1990-11-14 하라 레이노스께 슬라이드 프로젝터
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
ES2172535T3 (es) 1993-04-27 2002-10-01 Smithkline Beecham Corp Antagonistas de los receptores de la endotelina.
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
WO1996008466A1 (en) * 1994-09-12 1996-03-21 Takeda Chemical Industries, Ltd. Benzocycloalkene compounds, their production and use
JP3908798B2 (ja) * 1994-09-12 2007-04-25 武田薬品工業株式会社 ベンゾシクロアルケン類、その製造法および剤
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
US6025328A (en) * 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US7141603B2 (en) * 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents

Also Published As

Publication number Publication date
WO2007019308A3 (en) 2007-07-12
US20080306147A1 (en) 2008-12-11
WO2007019308A2 (en) 2007-02-15
JP2009503110A (ja) 2009-01-29
EP1909783A4 (de) 2010-08-04
EP1909783A2 (de) 2008-04-16
US7655695B2 (en) 2010-02-02
EP1909783B1 (de) 2011-10-12
JP4989648B2 (ja) 2012-08-01

Similar Documents

Publication Publication Date Title
ATE527998T1 (de) Illudin-analoga als krebsmittel
BRPI0608175A2 (pt) método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
IL180725A0 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
CU24269B1 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
MX349144B (es) Supresion de tumores utilizando perfundido placentario humano y celulas destructoras naturales intermediarias derivadas de la placenta humana.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
TW200942552A (en) Combination therapy with c-Met and HER antagonists
SI1404811T1 (sl) Ogljikov monoksid izboljša rezultate pri presaditvi tkiva in organov ter prepreči apoptozo
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
IN2014DN08886A (de)
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
EP1712235A3 (de) Kombinationstherapy mittels eines niedermolekularen Inhibitors der Interaktion des Oncogens MDM2 mit dem Transkriptionsfaktor P53
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
ECSP066457A (es) 5-arilpirimidinas como agentes anti-cancer
ECSP066458A (es) 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties